We are live on ! Find out more
VTGN icon

VistaGen Therapeutics

28 hedge funds and large institutions have $2.4M invested in VistaGen Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

566% more capital inflows, than outflows

Capital inflows: $791K | Capital outflows: $119K

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

12% more funds holding

Funds holding: 25 → 28 (+3)

1.89% more ownership

Funds ownership: 4.91% → 6.81% (+1.9%)

Holders
28
Holders Change
+3
Holders Change %
+12%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VTGN Hedge Fund Activity: Q3 2020 in Review

28 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2020, worth a combined $2.4M — up 81% from $1.33M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VTGN positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $538K. The largest seller was UBS Group, cutting an estimated $39.5K.

  • 28 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2020, up from 25 in Q2 2020.
  • Funds reported $2.4M of VistaGen Therapeutics stock for Q3 2020, up 81% quarter-over-quarter.
  • 5 funds opened new VistaGen Therapeutics positions in Q3 2020 and 2 closed out, a net change of +3 holders.
  • The largest VistaGen Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $538K added.
  • The largest VistaGen Therapeutics seller in Q3 2020 was UBS Group, an estimated $39.5K sold.

Based on aggregated 13F filings for Q3 2020.